OrbiMed’s Repare Therapeutics RPTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-3,322,488
| Closed | -$8.64M | – | 128 |
|
|
2025
Q4 | $8.64M | Hold |
3,322,488
| – | – | 0.18% | 83 |
|
|
2025
Q3 | $5.85M | Hold |
3,322,488
| – | – | 0.14% | 83 |
|
|
2025
Q2 | $4.62M | Hold |
3,322,488
| – | – | 0.12% | 80 |
|
|
2025
Q1 | $3.28M | Hold |
3,322,488
| – | – | 0.08% | 87 |
|
|
2024
Q4 | $4.35M | Hold |
3,322,488
| – | – | 0.09% | 89 |
|
|
2024
Q3 | $11.4M | Hold |
3,322,488
| – | – | 0.21% | 77 |
|
|
2024
Q2 | $11M | Hold |
3,322,488
| – | – | 0.22% | 72 |
|
|
2024
Q1 | $15.6M | Hold |
3,322,488
| – | – | 0.29% | 73 |
|
|
2023
Q4 | $24.3M | Hold |
3,322,488
| – | – | 0.48% | 59 |
|
|
2023
Q3 | $40.1M | Hold |
3,322,488
| – | – | 0.85% | 43 |
|
|
2023
Q2 | $35.2M | Hold |
3,322,488
| – | – | 0.64% | 50 |
|
|
2023
Q1 | $32.7M | Hold |
3,322,488
| – | – | 0.64% | 50 |
|
|
2022
Q4 | $48.9M | Hold |
3,322,488
| – | – | 0.93% | 40 |
|
|
2022
Q3 | $40.3K | Hold |
3,322,488
| – | – | 0.75% | 50 |
|
|
2022
Q2 | $46.5K | Hold |
3,322,488
| – | – | 0.84% | 37 |
|
|
2022
Q1 | $47.3M | Hold |
3,322,488
| – | – | 0.77% | 40 |
|
|
2021
Q4 | $70.1M | Hold |
3,322,488
| – | – | 0.9% | 38 |
|
|
2021
Q3 | $87.2M | Sell |
3,322,488
-103,837
| -3% | -$3.35M | 0.96% | 31 |
|
|
2021
Q2 | $107M | Hold |
3,426,325
| – | – | 1.08% | 30 |
|
|
2021
Q1 | $105M | Hold |
3,426,325
| – | – | 0.98% | 29 |
|
|
2020
Q4 | $118M | Hold |
3,426,325
| – | – | 1.03% | 27 |
|
|
2020
Q3 | $105M | Hold |
3,426,325
| – | – | 1.33% | 22 |
|
|
2020
Q2 | $106M | Buy |
+3,426,325
| New | +$110M | 1.5% | 22 |
|
OrbiMed's RPTX Position: Q1 2026 in Review
OrbiMed sold out of Repare Therapeutics (RPTX) in Q1 2026, closing a stake of 3,322,488 shares — an estimated $8.64M sold.
OrbiMed first reported a position in RPTX in Q2 2020 and held it in 23 quarters. The position peaked at $118M in Q4 2020. 0 funds tracked by Wall St. Rank hold RPTX as of Q1 2026.
- OrbiMed reported no remaining Repare Therapeutics position as of Q1 2026 after selling out during the quarter.
- OrbiMed sold 3,322,488 Repare Therapeutics shares in Q1 2026, an estimated $8.64M.
- OrbiMed first reported a position in Repare Therapeutics in Q2 2020 and held it in 23 quarters.
- OrbiMed's Repare Therapeutics position peaked at $118M in Q4 2020.
- 0 funds tracked by Wall St. Rank held Repare Therapeutics as of Q1 2026.
Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.